Close Menu

NEW YORK (GenomeWeb) – Fluidigm has announced that it has entered a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease researchers.

According to the partners, researchers will be able to expedite the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels using Fluidigm's automated microfluidic systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.